rilpivirina + emtricitabina + tenofovir — Competitive Intelligence Brief

rilpivirina + emtricitabina + tenofovir (rilpivirina + emtricitabina + tenofovir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + 2 NRTIs). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NNRTI + 2 NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

rilpivirina + emtricitabina + tenofovir (rilpivirina + emtricitabina + tenofovir) — Hospital Universitari Vall d'Hebron Research Institute. This combination inhibits HIV reverse transcriptase through three complementary mechanisms: rilpivirina as a non-nucleoside reverse transcriptase inhibitor (NNRTI) and emtricitabina and tenofovir as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rilpivirina + emtricitabina + tenofovir TARGET	rilpivirina + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Tenofovir disoproxil/emtricitabine/efavirenz	Tenofovir disoproxil/emtricitabine/efavirenz	Sheba Medical Center	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Tenofovir, emtricitabine, lopinavir/r	Tenofovir, emtricitabine, lopinavir/r	Hospital Clinic of Barcelona	marketed	Antiretroviral combination (NRTI + PI)	HIV reverse transcriptase, HIV protease
ZDV+3TC+LPV/r	ZDV+3TC+LPV/r	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
B/FTC/TAF	B/FTC/TAF	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + 2 NRTIs) class)

1. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
2. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class